Sunday, February 21, 2021 4:17:15 PM
In all the expected trials, CV included, Brilacidin is being tested at dosages below, or equal, to those given in prior trials where no safety issues were encountered. So why would one expect safety problems now?
In terms of efficacy, especially for CV, with an SI of 426 how can one expect anything but success with an extremely high level of confidence? If it doesn't do great, than the SI used by medicine is an absolute joke and doesn't mean squat. So are you saying you think the SI is just pure BS?
Is there risk, yes, but "high, high" risk? In my opinion, no.
I know we differ in viewpoint and I respect yours, but I tend to believe you are viewing Brilacidin as the same kind of drug you have seen tested in years past where they really didn't know squat about it prior to the trials. The many years of using computational screening IMO makes Brilacidin a whole new animal of drug.
Kind of like the recent landing on Mars, could this have been done years ago without the computer power we now possess to limit the odds of failure? Same thing with our drug compared to prior drugs.
Hope I am right on this subject so we both succeed in our investment.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM